Increase in antibody-dependent cellular cytotoxicity (ADCC) in a patient with advanced colorectal carcinoma carrying a KRAS mutation under lenalidomide therapy

References

• Wu L, Parton A, Lu L, Adams M, Schafer P, Bartlett JB. Lenalidomide enhances antibody-dependent cellular cytotoxicity of solid tumor cells in vitro: influence of host immune and tumor markers. Cancer Immunol Immunother 2011; 60:61 - 73; http://dx.doi.org/10.1007/s00262-010-0919-9; PMID: 20848094
   PubMed Web of Science ®Google Scholar
• Ströhlein MA, Grützner KU, Schildberg FW, Heiss MM. Induction of cytotoxicity against autologous tumour cells by interleukin-12: evidence for intrinsic anti-tumor immune capacity in curatively resected gastrointestinal tumour patients. Cancer Immunol Immunother 2002; 51:505 - 12; http://dx.doi.org/10.1007/s00262-002-0310-6; PMID: 12357322
   PubMed Web of Science ®Google Scholar
• Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011; 144:646 - 74; http://dx.doi.org/10.1016/j.cell.2011.02.013; PMID: 21376230
   PubMed Web of Science ®Google Scholar
• Vieweg J, Su Z, Dahm P, Kusmartsev S. Reversal of tumor-mediated immunosuppression. Clin Cancer Res 2007; 13:727s - 32s; http://dx.doi.org/10.1158/1078-0432.CCR-06-1924; PMID: 17255301
   PubMed Web of Science ®Google Scholar
• Kalmadi S, Baz R, Mahindra A. Lenalidomide: the emerging role of a novel targeted agent in malignancies. Drugs Today (Barc) 2007; 43:85 - 95; http://dx.doi.org/10.1358/dot.2007.43.2.1037480; PMID: 17353946
   PubMed Web of Science ®Google Scholar
• Bartlett JB, Dredge K, Dalgleish AG. The evolution of thalidomide and its IMiD derivatives as anticancer agents. Nat Rev Cancer 2004; 4:314 - 22; http://dx.doi.org/10.1038/nrc1323; PMID: 15057291
   PubMed Web of Science ®Google Scholar
• Bartlett JB, Tozer A, Stirling D, Zeldis JB. Recent clinical studies of the immunomodulatory drug (IMiD) lenalidomide. Br J Cancer 2005; 93:613 - 9; http://dx.doi.org/10.1038/sj.bjc.6602774; PMID: 16222306
   PubMed Web of Science ®Google Scholar
• Zhang L, Qian Z, Cai Z, Sun L, Wang H, Bartlett JB, Yi Q, Wang M. Synergistic antitumor effects of lenalidomide and rituximab on mantle cell lymphoma in vitro and in vivo. Am J Hematol 2009; 84:553 - 9; http://dx.doi.org/10.1002/ajh.21468; PMID: 19565649
   PubMed Web of Science ®Google Scholar
• Henry JY, Lu L, Adams M, Meyer B, Bartlett JB, Dalgleish AG, Galustian C. Lenalidomide enhances the anti-prostate cancer activity of docetaxel in vitro and in vivo. Prostate 2012; 72:856 - 67; http://dx.doi.org/10.1002/pros.21488; PMID: 21968939
   PubMed Web of Science ®Google Scholar
• Sanborn SL, Gibbons J, Krishnamurthi S, Brell JM, Dowlati A, Bokar JA, Nock C, Horvath N, Bako J, Remick SC, et al. Phase I trial of docetaxel given every 3 weeks and daily lenalidomide in patients with advanced solid tumors. Invest New Drugs 2009; 27:453 - 60; http://dx.doi.org/10.1007/s10637-008-9200-x; PMID: 19011760
   PubMed Web of Science ®Google Scholar
• Kalmadi S, Davis M, Dowlati A, O’Keefe S, Cline-Burkhardt M, Pelley RJ, Borden E, Dreicer R, Bukowski R, Mekhail T. Phase I trial of three-weekly docetaxel, carboplatin and oral lenalidomide (Revlimid) in patients with advanced solid tumors. Invest New Drugs 2007; 25:211 - 6; http://dx.doi.org/10.1007/s10637-006-9025-4; PMID: 17103043
   PubMed Web of Science ®Google Scholar
• Zhu D, Corral LG, Fleming YW, Stein B. Immunomodulatory drugs Revlimid (lenalidomide) and CC-4047 induce apoptosis of both hematological and solid tumor cells through NK cell activation. Cancer Immunol Immunother 2008; 57:1849 - 59; http://dx.doi.org/10.1007/s00262-008-0512-7; PMID: 18392823
   PubMed Web of Science ®Google Scholar
• Bartlett JB, Michael A, Clarke IA, Dredge K, Nicholson S, Kristeleit H, Polychronis A, Pandha H, Muller GW, Stirling DI, et al. Phase I study to determine the safety, tolerability and immunostimulatory activity of thalidomide analogue CC-5013 in patients with metastatic malignant melanoma and other advanced cancers. Br J Cancer 2004; 90:955 - 61; http://dx.doi.org/10.1038/sj.bjc.6601579; PMID: 14997189
   PubMed Web of Science ®Google Scholar
• Reynolds CP, Kang MH, Keir ST, Gorlick R, Kolb EA, Lock R, Maris JM, Carol H, Morton CL, Billups CA, et al. Initial testing of lenalidomide by the pediatric preclinical testing program. Pediatr Blood Cancer 2011; 57:606 - 11; http://dx.doi.org/10.1002/pbc.22877; PMID: 21360651
   PubMed Web of Science ®Google Scholar
• Wolchok JD, Weber JS, Maio M, Neyns B, Harmankaya K, Chin K, Cykowski L, de Pril V, Humphrey R, Lebbé C. Four-year survival rates for patients with metastatic melanoma who received ipilimumab in phase II clinical trials. Ann Oncol 2013; 24:2174 - 80; http://dx.doi.org/10.1093/annonc/mdt161; PMID: 23666915
   PubMed Web of Science ®Google Scholar
• Wolchok JD, Hoos A, O’Day S, Weber JS, Hamid O, Lebbé C, Maio M, Binder M, Bohnsack O, Nichol G, et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res 2009; 15:7412 - 20; http://dx.doi.org/10.1158/1078-0432.CCR-09-1624; PMID: 19934295
   PubMed Web of Science ®Google Scholar
• Denecke T, Rau B, Hoffmann KT, Hildebrandt B, Ruf J, Gutberlet M, Hünerbein M, Felix R, Wust P, Amthauer H. Comparison of CT, MRI and FDG-PET in response prediction of patients with locally advanced rectal cancer after multimodal preoperative therapy: is there a benefit in using functional imaging?. Eur Radiol 2005; 15:1658 - 66; http://dx.doi.org/10.1007/s00330-005-2658-4; PMID: 15806369
   PubMed Web of Science ®Google Scholar
• Overdijk MB, Verploegen S, van den Brakel JH, Lammerts van Bueren JJ, Vink T, van de Winkel JG, Parren PW, Bleeker WK. Epidermal growth factor receptor (EGFR) antibody-induced antibody-dependent cellular cytotoxicity plays a prominent role in inhibiting tumorigenesis, even of tumor cells insensitive to EGFR signaling inhibition. J Immunol 2011; 187:3383 - 90; http://dx.doi.org/10.4049/jimmunol.1003926; PMID: 21832160
   PubMed Web of Science ®Google Scholar
• Kasper S, Breitenbuecher F, Reis H, Brandau S, Worm K, Köhler J, Paul A, Trarbach T, Schmid KW, Schuler M. Oncogenic RAS simultaneously protects against anti-EGFR antibody-dependent cellular cytotoxicity and EGFR signaling blockade. Oncogene 2013; 32:2873 - 81; http://dx.doi.org/10.1038/onc.2012.302; PMID: 22797062
   PubMed Web of Science ®Google Scholar